Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2008536rdf:typepubmed:Citationlld:pubmed
pubmed-article:2008536lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2008536lifeskim:mentionsumls-concept:C0003289lld:lifeskim
pubmed-article:2008536pubmed:issue1lld:pubmed
pubmed-article:2008536pubmed:dateCreated1991-4-29lld:pubmed
pubmed-article:2008536pubmed:abstractText1. Substance abuse and post-psychotic depression are both frequently encountered concomitants of schizophrenia. 2. Substance abuse may be associated with depression-like symptomatology in the course of schizophrenia, and patients may attempt to self-medicate these symptoms with substances of abuse. 3. Antidepressant medication has been found to be a useful adjunct to treatment in at least some cases of substance abuse and some cases of post-psychotic depression. 4. Preliminary evidence exists suggesting that adjunctive antidepressant medication, added to a neuroleptic, may be useful for at least some stable dysphoric substance-abusing schizophrenic patients. 5. It is important to attempt to rule out even subtle neuroleptic-induced akinesia in such patients with a vigorous trial of antiparkinsonian medication.lld:pubmed
pubmed-article:2008536pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2008536pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2008536pubmed:languageenglld:pubmed
pubmed-article:2008536pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2008536pubmed:citationSubsetIMlld:pubmed
pubmed-article:2008536pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2008536pubmed:statusMEDLINElld:pubmed
pubmed-article:2008536pubmed:issn0278-5846lld:pubmed
pubmed-article:2008536pubmed:authorpubmed-author:SirisS GSGlld:pubmed
pubmed-article:2008536pubmed:authorpubmed-author:MasonS ESElld:pubmed
pubmed-article:2008536pubmed:authorpubmed-author:BermanzohnP...lld:pubmed
pubmed-article:2008536pubmed:authorpubmed-author:ShuwallM AMAlld:pubmed
pubmed-article:2008536pubmed:issnTypePrintlld:pubmed
pubmed-article:2008536pubmed:volume15lld:pubmed
pubmed-article:2008536pubmed:ownerNLMlld:pubmed
pubmed-article:2008536pubmed:authorsCompleteYlld:pubmed
pubmed-article:2008536pubmed:pagination1-13lld:pubmed
pubmed-article:2008536pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2008536pubmed:meshHeadingpubmed-meshheading:2008536-...lld:pubmed
pubmed-article:2008536pubmed:meshHeadingpubmed-meshheading:2008536-...lld:pubmed
pubmed-article:2008536pubmed:meshHeadingpubmed-meshheading:2008536-...lld:pubmed
pubmed-article:2008536pubmed:meshHeadingpubmed-meshheading:2008536-...lld:pubmed
pubmed-article:2008536pubmed:year1991lld:pubmed
pubmed-article:2008536pubmed:articleTitleAntidepressant for substance-abusing schizophrenic patients: a minireview.lld:pubmed
pubmed-article:2008536pubmed:affiliationHillside Hospital Division of the Long Island Jewish Medical Center, N.Y.lld:pubmed
pubmed-article:2008536pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2008536pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2008536pubmed:publicationTypeReviewlld:pubmed